You are on page 1of 2

DAFTAR PUSTAKA

1. S, Tyagi, et al. 2010. Stevens-Johnson syndrome: a life threatening skin


disorder. J Chem Pharm Res 2010; 2 (2): 618-26.
2. Patel K, Barvallaya M, Sharma D, Tripathi C. 2013. A systematic review
of the drug-induced Stevens-Johnson syndrome and toxic epidermal
necrolysis in Indian population. IJDVL 2013; 79 (3): 389-98.
3. Kwang T, Kian S. Profile and pattern of Stevens-Johnson syndrome and
toxic epidermal necrolysis in a General Hospital in Singapore: treatment
outcome. Acta Derm Venereol 2012; 92: 62-6.
4. Harr T, French. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Chem Immmunol Allergy 2012; 97: 149-66.
5. Sukmana, Nanang, dkk. 2014. Buku Ajar Ilmu Penyakit Dalam.Ed.6.
Jakarta: Interna Publising Pusat Penerbitan Ilmu Penyakit Dalam
Diponegoro.
6. James, William D, et al. 2011. AndrewsDisease of the Skin Clinical
Dermatology. Ed.11. Canada: Saunders Elsevier.
7. Acetaminophen induced Steven Johnson syndrome-toxic epidermal
necrolysis overlap. Khawaja A, Shahab A, Hussain SA. J Pak Med Assoc.
2012 May; 62(5):524-7.
8. Permenkes. 2014. Panduan Praktik Klinis bagi Dokter di Fasilitas
Pelayanan Kesehatan Primer.Jakarta: Permenkes.
9. NHS. 2016. Stevens Johnson Syndrome. London: United Kingdom.
10. Deore SS, Dandekar RC, Mahajan AM, Shiledar VV. Drug induced-
Stevens Johnson syndrome: A case report. Int J Sci Stud. 2014;2:847
11. A systematic review of the drug-induced Stevens-Johnson syndrome and
toxic epidermal necrolysis in Indian population. Patel TK, Barvaliya MJ,
Sharma D, Tripathi C. Indian J Dermatol Venereol Leprol. 2013 May-Jun;
79(3):389-98.
12. Cutaneus drug reaction. David A Khan. 2012. American Academy of
Allergy, Ashtma & Immunology.
13. Kohanim S, Palioura S, Saeed HN, Akpek EK, Amescua G, Basu S, et al.
Stevens-Johnson syndrome/toxic epidermal necrolysis--a comprehensive
review and guide to therapy. I. Systemic Disease. Ocul Surf 2016;14:2-19.

14. Ueta M, Kaniwa N, Sotozono C, Tokunaga K, Saito Y, Sawai H, et al. In-


dependent strong association of HLA-A*02:06 and HLA-B*44:03 with

23
cold medicine-related Stevens-Johnson syndrome with severe mucosal
involvement. Sci Rep 2014;4:4862.

15. Saeed HN, Chodosh J. Immunologic mediators in Stevens-Johnson syn-


drome and toxic epidermal necrolysis. Semin Ophthalmol 2016;31:85- 90.
16. Ocular Manifestations of Stevens- Johnson Syndrome and Toxic
Epidermal Necrolysis. Min Ho Kang. Department of Ophthalmology,
Hanyang University College of Medicine, Seoul; 2Department of
Ophthalmology, Hanyang University Guri Hospital, Guri, Korea. 2016
17. Sher N, Knowles S. Cutaneus adverse drug eruption. In: Goldsmith LA,
Katz SI, Gilcherst BA, Paller AS, Leffell DJ, Wolf K, editors.

th
Fritzpatricks Dermatology General Medicine. 8 editon. New York. Mc
Graw Hill; 2013.p.865-78.
18. Rahmawati YW dan Indramaya DM. 2016. A Retrospective Study: Steven-
Johnson Syndrome and Toxic Epidermal Necrolysis. 2016. Surabaya:
Departemen Kulit dan Kelamin Rumah Sakit Umum Daerah Dr. Soetomo
Surabaya.

19. Hamzah, M. 2007. ilmu penyakit kulit dan kelamin. edisi 5. Jakarta:
Fakultas Kedokteran Universitas Indonesia.

20. Karsenda. 2013. Pemberian Kortikosteroid Pada Pasien Sindrom Steven-


Johnson . Fakultas Kedokteran Universitas Lampung

21. Verma C, Vasudevan, Pragasan. Severe cutaneus adverse drug reaction.


Elseiver J 2013; 56: 375-83.

23